Work for Akero Therapeutics, Inc.?

Claim Your Profile

Akero Therapeutics, Inc. Logo Image

Akero Therapeutics, Inc.

Akero Therapeutics, Inc. Banner Image

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

2019 Annual Report and Form 10K

Akero Therapeutics, Inc.

Akero Therapeutics, Inc. has reached its limit for free report views.

About Akero Therapeutics, Inc.

11-50 Employees
Based in Cambridge, Massachusetts

Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients. The Company's lead product candidate, efruxifermin, has been evaluated in a 16-week Phase 2a clinical trial, the BALANCED study. Akero Therapeutics is headquartered in South San Francisco, CA.

Ticker:
AKRO
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol